Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 55% Improvement Relative Risk ICU admission 66% Mortality (b) 28% ICU admission (b) 26% c19ivm.org Mayer et al. Ivermectin for COVID-19 EARLY TREATMENT Is early treatment with ivermectin beneficial for COVID-19? Retrospective 21,232 patients in Argentina Lower mortality (p<0.0001) and ICU admission (p<0.0001) Mayer et al., Frontiers in Public Health, doi:10.3389/fpubh.2022.813378 Favors ivermectin Favors control
Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients
Mayer et al., Frontiers in Public Health, doi:10.3389/fpubh.2022.813378 (date from earlier preprint)
Mayer et al., Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients, Frontiers in Public Health, doi:10.3389/fpubh.2022.813378 (date from earlier preprint)
Sep 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 21,232 patients in Argentina, 3,266 assigned to ivermectin treatment, showing lower mortality with treatment. Greater benefits were seen for patients >40, and a dose dependent response was found. For more discussion see [twitter.com].
See also: [doyourownresearch.substack.com].
risk of death, 55.1% lower, RR 0.45, p < 0.001, treatment 3,266, control 17,966, adjusted per study, odds ratio converted to relative risk, Figure 3, multivariable.
risk of ICU admission, 65.9% lower, RR 0.34, p < 0.001, treatment 3,266, control 17,966, adjusted per study, odds ratio converted to relative risk, Figure 3, multivariable.
risk of death, 27.6% lower, RR 0.72, p = 0.03, treatment 3,266, control 17,966, odds ratio converted to relative risk, unadjusted.
risk of ICU admission, 26.0% lower, RR 0.74, p = 0.13, treatment 3,266, control 17,966, odds ratio converted to relative risk, unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mayer et al., 23 Sep 2021, retrospective, Argentina, peer-reviewed, 14 authors, dosage 540μg/kg days 1-5, mean prescribed dose.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: ORIGINAL RESEARCH published: 22 February 2022 doi: 10.3389/fpubh.2022.813378 Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients Marcos Alejandro Mayer 1,2,3*† , Alejandro Krolewiecki 3,4† , Alejandro Ferrero 1 , Marcelo Bocchio 1 , Juan Barbero 1 , Marcos Miguel 1 , Ariel Paladini 1 , Carlos Delgado 1 , Juan Ramón Ojeda 1 , Claudia Elorza 1 , Ana Bertone 1 , Pedro Emanuel Fleitas 3,4 , Gustavo Vera 1 and Mario Rubén Kohan 1 1 Ministerio de Salud de la Provincia de La Pampa, Santa Rosa, Argentina, 2 Fundación Centro de Salud e Investigaciones Médicas, Santa Rosa, Argentina, 3 Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina, 4 Instituto de Investigaciones de Enfermedades Tropicales, Universidad Nacional de Salta, Sede Regional Orán, Salta, Argentina Edited by: Shisan Bao, The University of Sydney, Australia Reviewed by: Susanta Kumar Ghosh, National Institute of Malaria Research (ICMR), India Guilherme Dias de Melo, Institut Pasteur, France *Correspondence: Marcos Alejandro Mayer marcos.mayer@gmail.com † These authors have contributed equally to this work Specialty section: This article was submitted to Infectious Diseases – Surveillance, Prevention and Treatment, a section of the journal Frontiers in Public Health Received: 11 November 2021 Accepted: 31 January 2022 Published: 22 February 2022 Citation: Mayer MA, Krolewiecki A, Ferrero A, Bocchio M, Barbero J, Miguel M, Paladini A, Delgado C, Ojeda JR, Elorza C, Bertone A, Fleitas PE, Vera G and Kohan MR (2022) Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients. Front. Public Health 10:813378. doi: 10.3389/fpubh.2022.813378 Background: In the absence of antiviral alternatives, interventions under research for COVID-19 might be offered following guidelines from WHO for monitored emergency use of unregistered and experimental interventions (MEURI). Ivermectin is among several drugs explored for its role against SARS-CoV-2, with a well-known safety profile but conflicting data regarding clinical utility for COVID-19. The aim of this report is to inform on the results of a MEURI Program of high-dose ivermectin in COVID-19 carried out by the Ministry of Health of the Province of La Pampa, Argentina. Methods: COVID-19 subjects, within 5 days of symptoms onset were invited to participate in the program, which consisted in the administration of ivermectin 0.6 mg/kg/day for 5 days plus standard of care. Active pharmacosurveillance was performed for 21 days, and hepatic laboratory assessments were performed in a subset of patients. Frequency of Intensive Care Unit (ICU) admission and COVID-19-related mortality of subjects in the ivermectin intention to treat group were compared with that observed in inhabitants of the same province during the same period not participating in the program. Results: From 21,232 subjects with COVID-19, 3,266 were offered and agreed to participate in the ivermectin program and 17,966 did not and were considered as controls. A total of 567 participants reported 819 adverse events (AEs); 3.13% discontinued ivermectin due to adverse events. ICU admission was significantly lower in the ivermectin group compared to controls among participants ≥40 year-old (1.2 vs. 2.0%, odds ratio 0.608; p = 0.024). Similarly, mortality was lower in the ivermectin group in the full group analysis (1.5 vs. 2.1%, odds ratio 0.720; p = 0.029), as well as in..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit